Antibodies
18 August 2010
Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma13 August 2010
NICE concludes omalizumab is not an effective use of NHS resources for children under 1211 August 2010
Biotest AG: Development of BT-062 makes further progress with start of a new clinical trial10 August 2010
Genmab Announces Top-Line Interim Results for Ofatumumab in Diffuse Large B-Cell Lymphoma10 August 2010
Immunomodulatory antibody BT-061 shows competitive efficacy in the indication Rheumatoid Arthritis28 July 2010
Astellas to Pay $295 Million to Extend License of Regeneron’s VelocImmune Antibody Technology through 202319 July 2010
Amgen gets rapid FDA review for denosumabNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports